Targeting EGFR signalling pathway in triple negative breast cancer
<p>Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic response...
المؤلف الرئيسي: | |
---|---|
مؤلفون آخرون: | |
التنسيق: | أطروحة |
اللغة: | English |
منشور في: |
2014
|
الموضوعات: |